TICKERNERD
Menu
XENEXENEHealthcare · Biotechnology

XENE Stock Forecast: Xenon Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$59
−0.26% on the day

The 18 Wall Street analysts covering Xenon Pharmaceuticals, Inc. hold a median 12-month price target of $80 — +36.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$5.7B
Ticker Nerd rank
50 / 100
Median analyst target
$80
Analysts covering
18
Revenue$0.0
Operating income−$123.2M
Net income−$110.7M
Free cash flow−$95.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.9%
1M
−7.2%
YTD
+30.9%
1Y
+57.6%
From 52W high
−17.3%
From 52W low
+64.5%
$36
$71
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

XENE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Xenon Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
50 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
92
Momentum
84
Value
66
Revisions
63
Quality
47
Issuance
40
Accruals
36
Growth
29
Size
22

Volatility (92): The share price has been relatively steady.

Growth (29): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (22): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

XENE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XENE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100Oct 25Jan 26Apr 26Jul 26XENEHigh $100Median $80Low $69

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says18 analysts
18 Buy0 Hold0 Sell
Low $69Median $80High $100

The green dot is the last close — the median target sits +36.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Aug 2026RBC CapitalMaintainsOutperform$82 → $81
27 May 2026JP MorganMaintainsOverweight$80 → $82
27 May 2026JP MorganMaintainsOverweight—
12 May 2026JP MorganMaintainsOverweight—
8 May 2026NeedhamMaintainsBuy—
8 May 2026RBC CapitalMaintainsOutperform—
16 Mar 2026WedbushMaintainsOutperform—
10 Mar 2026Deutsche BankMaintainsBuy—
10 Mar 2026HC Wainwright & Co.MaintainsBuy—
10 Mar 2026WedbushMaintainsOutperform—
10 Mar 2026Wells FargoMaintainsOverweight—
9 Mar 2026BairdMaintainsOutperform—
9 Mar 2026NeedhamMaintainsBuy—
27 Feb 2026NeedhamMaintainsBuy—
27 Feb 2026Wells FargoMaintainsOverweight—
24 Feb 2026Wolfe ResearchInitiatesOutperform—
9 Jan 2026JP MorganMaintainsOverweight—
11 Dec 2025Wells FargoMaintainsOverweight—
18 Nov 2025JP MorganMaintainsOverweight—
4 Nov 2025NeedhamReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XENE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

XENE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Xenon Pharmaceuticals, Inc. returned +57.6% against +17.5% for the S&P 500, dividends included.

XENE vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180200Oct 25Jan 26Apr 26Jul 26XENES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

XENE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
1
Fundamentals

Xenon Pharmaceuticals, Inc. (XENE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−13.5×

Cheaper than 94% of US stocks

Price / sales
757.3×

Cheaper than 1% of US stocks

Price / book
4.6×

Cheaper than 22% of US stocks

EV / EBITDA
−10.8×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−4974.3%

Higher than 3% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−43.6%

Higher than 23% of US stocks

Return on assets
−28.0%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Xenon Pharmaceuticals, Inc. (XENE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Xenon Pharmaceuticals, Inc. has a market value of $5.7B and an enterprise value of $4.8B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$409.2M.

  • Diluted earnings per share, trailing twelve months: $−4.74.

  • Free cash flow in the twelve months to 30 June 2026: −$338.5M.

  • Shares outstanding: 96.8M.

  • Trailing P/E: −13.5×; forward P/E: −12.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Xenon Pharmaceuticals, Inc. employs 358 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

XENE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
XENEXenon Pharmaceuticals, Inc.$5.7B
50
LGNDLigand Pharmaceuticals, Inc.$5.6B
73
COGTCogent Biosciences, Inc.$5.7B
35
PTCTPTC Therapeutics, Inc.$5.5B
65
ERASErasca, Inc.$5.4B
55
DNTHDianthus Therapeutics, Inc.$5.8B
61
ORKAOruka Therapeutics, Inc.$6.1B
40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Xenon Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest XENE news & analysis

Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback

Investors Business Daily · 10 Sept 2026positive

Biohaven paused enrollment in a midstage study of its seizure treatment due to safety concerns, causing its stock to fall sharply on Thursday. The setback affects Biohaven's development program for the treatment.

Why it matters — A setback for a rival company's seizure treatment could be viewed favorably for XENE, as both companies compete in the epilepsy and seizure-treatment space.

Xenon to Present at Wells Fargo Healthcare Conference

GlobeNewsWire · 3 Sept 2026neutral

Xenon Pharmaceuticals announced it will present at an upcoming investor conference, the Wells Fargo Healthcare Conference. The announcement was made via press release on September 3, 2026, from the company's Vancouver, BC and Boston, MA offices.

Why it matters — A XENE watcher would care because this conference presentation gives investors an opportunity to hear directly from the company about its neuroscience-focused pipeline and business.

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 28 Aug 2026neutral

Xenon Pharmaceuticals announced equity inducement grants to five new non-officer employees, comprising 13,450 share options and 7,850 restricted share units, approved by the Compensation Committee with an effective date of August 27, 2026. The grants were issued as inducements material to the employees joining the company, in line with Nasdaq Listing Rule 5635(c)(4).

Why it matters — The announcement signals the company's continued hiring of new personnel through equity-based incentives, which may be of interest to XENE watchers tracking management and workforce developments.

Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026

GlobeNewsWire · 26 Aug 2026positive

Xenon Pharmaceuticals announced multiple data presentations at the 16th European Epilepsy Congress (EEC), taking place September 5-9, 2026, in Athens, Greece, highlighting Phase 3 X-TOLE2 clinical data and the rational polytherapy potential for azetukalner.

Why it matters — The presentations will showcase clinical data for azetukalner, a key development-stage compound, giving investors and watchers insight into its Phase 3 results and potential role in combination epilepsy therapy.

Xenon Pharmaceuticals: Strong Buy On Azetukalner NDA And MDD Expansion Opportunity

Seeking Alpha · 11 Aug 2026positive

Xenon Pharmaceuticals was upgraded to "Strong Buy" following positive phase 3 X-TOLE2 results for azetukalner in focal onset seizures. The company plans an NDA filing for azetukalner in FOS in Q3 2026, with X-TOLE3 supporting potential ex-US expansion, and phase 3 X-NOVA2 topline data for major depressive disorder expected in 1H 2027.

Why it matters — A XENE watcher would care because positive phase 3 results and the planned NDA filing for azetukalner, along with upcoming MDD data, mark key clinical and regulatory milestones for the company's pipeline.

FAQ

Frequently asked questions about XENE stock

What is the XENE stock price forecast for 2026-2027?

The 18 Wall Street analysts covering Xenon Pharmaceuticals, Inc. have a median 12-month price target of $80, with estimates ranging from $69 to $100. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is XENE stock a buy right now?

Of the 18 analysts covering Xenon Pharmaceuticals, Inc., 18 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xenon Pharmaceuticals, Inc. 50 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XENE?

As at 12 Sept 2026, Xenon Pharmaceuticals, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (92 of 100).

Will XENE stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +36.4% from the last close, and Ticker Nerd's factor model ranks Xenon Pharmaceuticals, Inc. 50 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the XENE stock forecast for 2030?

No analyst covering Xenon Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XENE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $69 to $100 over the next 12 months.

How has XENE stock performed over the past year?

Xenon Pharmaceuticals, Inc. returned +57.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Xenon Pharmaceuticals, Inc. do?

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company that develops therapies for neurological and psychiatric disorders.

What is the latest news on XENE?

The most recent item we track (Investors Business Daily, 10 Sept 2026): "Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback". Biohaven paused enrollment in a midstage study of its seizure treatment due to safety concerns, causing its stock to fall sharply on Thursday. The setback affects Biohaven's development program for the treatment.

Company

About Xenon Pharmaceuticals, Inc.

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company that develops therapies for neurological and psychiatric disorders. Xenon Pharmaceuticals Inc. concentrates on ion channel science and small-molecule drug discovery, with a pipeline centered on treatments for epilepsy and other central nervous system conditions. Its current programs include late-stage and early-stage candidates aimed at focal seizures, primary generalized tonic-clonic seizures, major depressive disorder, bipolar depression, and pain. The company operates as a single reportable segment focused on discovering, developing, and delivering therapeutics for patients with high unmet medical needs. Headquartered in Burnaby, British Columbia, Xenon Pharmaceuticals Inc. has an operating presence in North America and collaborates with clinical and research partners to advance its development programs.

CEO Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. · 358 employees · Canada · https://www.xenon-pharma.com